Targeting VEGF in cancer therapy

Current Problems in Cancer

Volumn 30, Issue 1, 2006, Pages 1-32

  Takimoto, Chris H ^b   Donovan, Erin A ^a   Kummar, Shivaani ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b National Cancer Institute ^*

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AE 941; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; AQM 674; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; DRUG METABOLITE; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IMATINIB; IRINOTECAN; OXALIPLATIN; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SU 12662; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP; VASCULOTROPIN; VATALANIB; VEGLIN; ANTIBODY; ANTISENSE OLIGONUCLEOTIDE; PROTEIN TYROSINE KINASE; VASCULOTROPIN A;

ANGIOGENESIS; ANOREXIA; AREA UNDER THE CURVE; ARTERY THROMBOSIS; ASTHENIA; BLEEDING; BREAST CANCER; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSE CALCULATION; DOSE RESPONSE; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; GENE EXPRESSION REGULATION; HEMATOLOGIC DISEASE; HEMATURIA; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPONATREMIA; IC 50; KIDNEY CARCINOMA; LIVER TOXICITY; LUNG CANCER; MAXIMUM TOLERATED DOSE; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PAIN; PROTEIN EXPRESSION; PROTEINURIA; QT PROLONGATION; RASH; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SKIN MANIFESTATION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; VEIN THROMBOSIS; VOMITING; WOUND HEALING IMPAIRMENT; BREAST TUMOR; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; KIDNEY TUMOR; LUNG TUMOR; NEOPLASM; PHYSIOLOGY;

ANTIBODIES; BREAST NEOPLASMS; CARCINOMA, RENAL CELL; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN-TYROSINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 31444437952     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/S0147-0272(05)00094-2     Document Type: Review

References (97)

1. N. Ferrara Vascular endothelial growth factor as a target for anticancer therapy Oncologist 9 2004 2 10
2. D. Hicklin, L. Ellis Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol 23 2005 1011 1027
3. A. Parikh, L. Ellis The vascular endothelial growth factor family and its receptors Hematol Oncol Clin N Am 18 2004 951 971
4. K. Xie, D. Wei, Q. Shi, S. Huang Constitutive and inducible expression and regulation of vascular endothelial growth factor Cytokine Growth Factor Rev 15 2004 297 324
5. J. DiSalvo, G. Conn, P. Trivedi Purification and characterization of a naturally occurring vascular endothelial growth factor-placenta growth factor heterodimer J Biol Chem 270 1995 7717 7723
6. N. Ton, G. Jayson Resistance to anti-VEGF agents Curr Pharmaceut Des 10 2004 51 64
7. N. Ferrara, K. Hillan, H.-P. Gerber, W. Novotny Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 2004 391 400
8. J. Holash, S. Davis, N. Papadopoulos VEGF-Trap a VEGF blocker with potent antitumor effects Proc Natl Acad Sci USA 99 2002 11393 11398
9. J. Dupont, L. Schwartz, J. Koutcher Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies Proc Am Soc Clin Oncol 2004 3009a
10. J. Konner, J. Dupont Use of soluble recombinant decoy receptor vascular endothelial growth factor Trap (VEGF Trap) to inhibit vascular endothelial growth factor activity Clin Colorectal Cancer 4 2004 S81 S85
11. J. Dupont, M. Rothenberg, D. Spriggs Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors Proc Am Soc Clin Oncol 2005 3029a
12. B. Morgan, A. Thomas, J. Drevs Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases results from two phase I studies J Clin Oncol 21 2003 3955 3964
13. J. Drevs, K. Mross, M. Medinger Phase I dose-escalation and pharmacokinetic (PK) study of the VEGF inhibitor PTK787/ZK 222584 (PTK/ZK) in patients with liver metastases Proc Am Soc Clin Oncol 2003 1142a
14. A. Thomas, B. Morgan, M. Horsfield Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer J Clin Oncol 23 2005 4162 4171
15. A. Ryan, S. Wedge ZD6474 a novel inhibitor of VEGFR and EGFR tyrosine kinase activity Br J Cancer 92 2005 S6 S13
16. H. Hurwitz, S. Holden, S. Eckhardt Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors Proc Am Soc Clin Oncol 2002 325a
17. J. Heymach ZD6474 clinical experience to date Br J Cancer 92 2005 S14 S20
18. S. Wilhelm, C. Carter, L. Tang BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109
19. D. Strumberg, H. Richly, R. Hilger Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors J Clin Oncol 23 2005 965 972
20. A.-M. O'Farrell, T. Abrams, H. Yuen SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo Blood 101 2003 3597 3605
21. D. Mendel, A. Laird, X. Xin In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 2003 327 337
22. L. Rosen, M. Mulay, J. Long Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors Proc Am Soc Clin Oncol 2003 765a
23. P. Traxler, P. Allegrini, R. Brandt AEE788 A dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity Cancer Res 64 2004 4931 4941
24. E. Martinelli, C. Takimoto, A. vanOosterom AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases preliminary phase I results Proc Am Soc Clin Oncol 2005 3039a
25. J. Baselga, F. Rojo, H. Dumez Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases a pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen Proc Am Soc Clin Oncol 2005 3028a
26. A. Levine, D. Quinn, G. Gorospe Phase I trial of anti-sense oligonucleotide vascular endothelial growth factor (VEGF-AS, Veglin) in patients with relapsed and refractory malignancies Proc Am Soc Clin Oncol 2004 3008a
27. Y. Takebayashi, S. Aklyama, K. Yamada Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma Cancer 78 1996 226 231
28. Y. Takahashi, Y. Kitadai, C. Bucana Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer Cancer Res 55 1995 3964 3968
29. J.-C. Lee, N.-H. Chow, S.-T. Wang, S.-M. Huang Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients Eur J Cancer 36 2000 748 753
30. L. Ellis Angiogenesis and its role in colorectal tumor and metastasis formation Semin Oncol 31 2004 3 9
31. F. Fan, J. Wey, M. McCarty Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells Oncogene 24 2005 2647 2653
32. F. Kabbinavar, H. Hurwitz, L. Fehrenbacher Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 2003 60 65
33. N. Petrelli, H. Douglass, L. Herrera GI Tumor Study Group Modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma A prospective randomized phase III trial J Clin Oncol 7 1989 1419 1426
34. L. Saltz, J. Kanowitz, N. Kerneny Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors J Clin Oncol 14 1996 2959 2967
35. H. Hurwitz, L. Fehrenbacher, W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
36. H. Hurwitz, L. Fehrenbacher, J. Hainsworth Bevacizumab in combination with fluorouracil and leucovorin An active regimen for first-line metastatic colorectal cancer J Clin Oncol 23 2005 3502 3508
37. F. Kabbinavar, J. Schulz, M. McCleod Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer Results of a randomized phase II trial J Clin Oncol 23 2005 3697 3705
38. F. Kabbinavar, J. Hambleton, R. Mass Combined analysis of efficacy The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer J Clin Oncol 23 2005 3706 3712
39. A. DeGramont, A. Figer, M. Seymour Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2000 2938 2947
40. B. Giantonio, P. Catalano, N. Meropol High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 Proc Am Soc Clin Oncol 2005 2a
41. G. Reddy The addition of bevacizumab to FOLFOX4 prolongs survival in relapsed colorectal cancer Interim data from the ECOG 3200 trial Clin Colorectal Cancer 4 2005 300 301
42. H. Chen, M. Mooney, M. Boron Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies An NCI Treatment Referral Center trial (TRC-0301) Proc Am Soc Clin Oncol 2004 3515a
43. L. Saltz, H. Lenz, H. Hochster Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer Proc Am Soc Clin Oncol 2005 3508a
44. L. Saltz, H. Lenz, H. Kindler Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer ASCO Gastrointest Cancer Symp 2005 169b
45. J. Klem Current studies with PTK787, an oral inhibitor of vascular endothelial growth factor, in colorectal cancer Clin Colorectal Cancer 3 2003 147 149
46. P. Tyagi Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer Preliminary results from the CONFIRM-1 trial Clin Colorectal Cancer 5 2005 24 26
47. T. Andre, C. Louvet, F. Maindrault-Goebel CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR Eur J Cancer 35 1999 1343 1347
48. T. Trarbach, A. Thomas, C. Bartel Preliminary phase I results of the oral, once-daily angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) in combination with chemotherapy for the treatment of metastatic colorectal cancer Eur J Cancer Suppl 1 2003 S91
49. W. Steward, A. Thomas, B. Morgan Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer Proc Am Soc Clin Oncol 2004 3556a
50. J. Hecht, T. Trarbach, E. Jaeger A randomized double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1) Proc Am Soc Clin Oncol 2005 LBA3
51. R. Bukowski Cytokine therapy for metastatic renal cell carcinoma Semin Urol Oncol 19 2001 148 154
52. B. Rini, E. Small Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma J Clin Oncol 23 2005 1028 1043
53. P. Crossey, K. Foster, F. Richards Molecular genetic investigations of the mechanism of tumorigenesis in von Hippel-Lindau disease analysis of allele loss in VHL tumors Hum Genet 93 1994 53 58
54. J. Gnarra, K. Tory, Y. Weng Mutations of the VHL tumour suppressor gene in renal carcinoma Nat Genet 7 1994 85 90
55. T. Shuin, K. Kondo, S. Torigoe Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas Cancer Res 54 1994 2852 2855
56. C. Gallou, D. Joly, A. Mejean Mutations of the VHL gene in sporadic renal cell carcinoma Definition of a risk factor for VHL patients to develop an RCC Hum Mutat 13 1999 464 475
57. P. Maxwell, M. Wiesener, G. Chang The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis Nature 399 1999 271 275
58. M. Cockman, N. Masson, D. Mole Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein J Biol Chem 275 2000 25733 25741
59. O. Iliopoulos, A. Levy, C. Jiang Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein Proc Natl Acad Sci USA 93 1996 10595 10599
60. J. Gnarra, S. Zhou, M. Merrill Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene Proc Natl Acad Sci USA 93 1996 10589 10594
61. X. Na, W. Guan, C. Ryan Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1α expression in renal cell carcinomas J Urol 170 2003 588 592
62. K. Turner, J. Moore, A. Jones Expression of hypoxia-inducible factors in human renal cancer Relationship to angiogenesis and to the von Hippel-Lindau gene mutation Cancer Res 62 2002 2957 2961
63. J. Yang, L. Haworth, R. Sherry A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 2003 427 434
64. D. Elaraj, D. White, S. Steinberg A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma J Immunother 27 2004 259 264
65. D. Spigel, J. Hainsworth, J. Sosman Bevacizumab and erlotonib in the treatment of patients with metastatic renal cell carcinoma (RCC) Update of a phase II multicenter trial Proc Am Soc Clin Oncol 2005 4540a
66. B. Rini, S. Halabi, J. Taylor Cancer and Leukemia Group B 90206 A randomized phase III trial of interferon-α or interferon-α plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma Clin Cancer Res 10 2004 2584 2586
67. D. George, D. Michaelson, W. Oh Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma Proc Am Soc Clin Oncol 2003 1548a
68. T. Ahmad, T. Eisen Kinase inhibition with BAY 43-9006 in renal cell carcinoma Clin Cancer Res 10 2004 6388s 6392s
69. P. O'Dwyer, M. Rosen, M. Gallagher Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma Proc Am Soc Clin Oncol 2005 3005a
70. M. Ratain, K. Flaherty, W. Stadler Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT) Proc Am Soc Clin Oncol 2004 4501a
71. R. Herbst, A. Onn, A. Sandler Angiogenesis and lung cancer Prognostic and therapeutic implications J Clin Oncol 23 2005 3243 3256
72. H. Han, J. Silverman, T. Santucci Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis Ann Surg Oncol 8 2001 72 79
73. G. Fontanini, P. Faviana, M. Lucchi A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma Br J Cancer 86 2002 558 563
74. M. Koukourakis, A. Giatromanolaki, P. Thorpe Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer Cancer Res 60 2000 3088 3095
75. D. Johnson, L. Fehrenbacher, W. Novotny Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2004 2184 2191
76. R. Herbst, D. Johnson, E. Mininberg Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotonib for patients with recurrent non-small-cell lung cancer J Clin Oncol 23 2005 2544 2555
77. D. Lee Multitargeted kinase inhibitors in non-small-cell lung cancer Oncol Brief 3 2005 1 3
78. E. Raefsky, D. Spigel, F. Greco Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by bevacizumab (B) in the treatment of limited-stage small cell lung cancer (SCLC) a phase II trial of the Minnie Pearl Cancer Research Network Proc Am Soc Clin Oncol 2005 7050a
79. J. Heymach, R.-P. Dong, I. Dimery ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC Results of the run-in phase of a two-part, randomized phase II study Proc Am Soc Clin Oncol 2004 3051a
80. J. Heymach, B. Johnson, J. Rowbottom A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel in patients with NSCLC Proc Am Soc Clin Oncol 2005 3023a
81. R. Herbst, B. Johnson, J. Rowbottom ZD6474 plus docetaxel in patients with previously treated NSCLC Results of a randomized, placebo-controlled phase II trial Lung Cancer 49 2005 S35 S36
82. R. Cohen, G. Simon, C. Langer Phase I trial of oral CP-547,632 (VEGFR2) in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 2004 3014a
83. N. Weidner, J. Semple, W. Welch, J. Folkman Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma N Engl J Med 324 1991 1 8
84. B. Schneider, K. Miller Angiogenesis of breast cancer J Clin Oncol 23 2005 1782 1790
85. G. Gasparini, M. Toi, M. Gion Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma J Natl Cancer Inst 89 1997 139 147
86. J. Ragaz, K. Miller, S. Badve Adverse association of expressed vascular endothelial growth factor (VEGF), Her2, Cox2, uPA and EMSY with long-term outcome of stage I-III breast cancer (BrCa). Results from the British Columbia Tissue Microarray Project Proc Am Soc Clin Oncol 2004 524a
87. M. Cobleigh, V. Langmuir, G. Sledge A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer Semin Oncol 30 2003 117 124
88. H. Burstein, L. Parker, J. Savoie Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer Breast Cancer Res Treat 76 2002 S115
89. B. Ramaswamy, C. Rhoades, K. Kendra CTEP-sponsored phase II trial of bevacizumab (Avastin®) in combination with docetaxel (Taxotere) in metastatic breast cancer Breast Cancer Res Treat 82 2003 S50
90. M. Pegram, C. Yeon, N. Ku Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF) Breast Cancer Res Treat 88 2004 S124
91. M. Dickler, H. Rugo, J. Caravelli Phase II trial of erlotonib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC) Proc Am Soc Clin Oncol 2004 2001a
92. T. Traina, M. Dickler, J. Caravelli A feasibility study of an aromatase inhibitor (AI), letrozole (L), and the antibody to vascular endothelial growth factor (VEGF), bevacizumab (B), in patients with hormone receptor-positive metastatic breast cancer (MBC) Proc Am Soc Clin Oncol 2005 796a
93. B. Overmoyer, P. Silverman, R. Leeming Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer Breast Cancer Res Treat 88 2004 S106
94. S. Wedam, J. Low, X. Yang A pilot study to evaluate response and angiogenesis after treatment with bevacizumab in patients with inflammatory breast cancer Proc Am Soc Clin Oncol 2004 578a
95. K. Miller, H. Rugo, M. Cobleigh Phase III trial of capecitabine (Xeloda) plus bevacizumab (Avastin) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane Breast Cancer Res Treat 76 2002 S37
96. K. Hillan, H. Koeppen, P. Tobin The role of VEGF expression in response to bevacizumab plus capecitabine in metastatic breast cancer (MBC) Proc Am Soc Clin Oncol 2003 766a
97. K. Miller, J. Trigo, C. Wheeler A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer Clin Cancer Res 11 2005 3369 3376